dNLR-Based Score Predicting Overall Survival Benefit for The Addition of Platinum-Based Chemotherapy to Pembrolizumab in Advanced NSCLC With PD-L1 Tumor Proportion Score ≥50%

The study represents one of the largest retrospective comparative analyses of first-line pembrolizumab (P) with and without chemotherapy (PCT) in PD-L1 TPS≥50% aNSCLC. In the propensity score matched cohort, no differences in OS between P and PCT were observed. A predictive score incorporating age, sex, smoking, histology and dNLR was developed, and appeared to predict OS with P and PCT.